MarketPulse

drug efficacy

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Stock Plummets 71% After FDA Rejects Lead Drug; Law Firm Launches Investigation

Aldeyra Therapeutics stock plunged 71% after FDA rejected its reproxalap dry eye drug, prompting a securities investigation by Rosen Law Firm.
ITDNOWALDXstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Block & Leviton Llp

Aldeyra Therapeutics Stock Plummets 65% After FDA Rejection; Securities Fraud Investigation Launched

Aldeyra Therapeutics ($ALDX) shares crashed 65% following FDA rejection of reproxalap for dry eye disease. Law firm Block & Leviton investigates potential securities fraud.
EOSENUTXALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Soleno Therapeutics Faces Class Action Over DCCR Safety Claims as Stock Plummets 27%

Robbins LLP launches class action against $SLNO over alleged investor deception regarding DCCR drug safety and efficacy for Prader-Willi syndrome treatment.
EOSEDRVNSLNOclass action lawsuitstock decline
The Motley FoolThe Motley Fool··Motley Fool Youtube

Novo Nordisk's Obesity Drug Underperforms Rival Zepbound in Late-Stage Trial

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.
LLYNVOclinical trialweight loss